Tuesday December 11, 2018

Study: Diabetes Treatment Gets Boost From ‘Surgery in a Pill’

Novel 'surgery in a pill' to reverse diabetes

0
//
Study: Diabetes Treatment Gets Boost From 'Surgery in a Pill'
Study: Diabetes Treatment Gets Boost From 'Surgery in a Pill'. (IANS)
Republish
Reprint

Researchers have developed “surgery in a pill” that can reduce post-meal blood sugar spikes and help reverse diabetes.

When the pill was administered in rats, it delivered a substance that could temporarily coat the intestine, forming a thin barrier that alters nutrient contact and lowers blood glucose response after a meal, the researchers said.

“We envision a pill that a patient can take before a meal that transiently coats the gut to replicate the effects of surgery,” said Jeff Karp, a bioengineer at the Brigham and Women’s Hospital (BWH) in Massachusetts, US.

After a meal, blood sugar levels rise and can stay elevated over time.

However, one hour after the pill was administered to the rats, the response to glucose was lowered by 47 per cent.

“What we’ve developed here is essentially, ‘surgery in a pill’,” added Yuhan Lee, a materials scientist in the BWH.

This response was temporary, and after three hours, the effect essentially disappeared, the study showed.

Representational image.
Representational image. Pixabay

For the study, published in the journal Nature Materials, the team selected a substance known as sucralfate — an FDA-approved drug that is used in the treatment of gastrointestinal ulcers — to adhere to the small intestine and then dissolve within a matter of hours.

Further, the team engineered the substance into a novel material that can coat the lining of the intestine without requiring activation by gastric acid.

The engineered compound, referred to as LuCI (Luminal Coating of the Intestine), can be made into a dry powdered form that can be encapsulated as a pill.

Also Read: Thyroid Dysfunction May Lead to Diabetes During Pregnancy

“We’ve used a bioengineering approach to formulate a pill that has good adhesion properties and can attach nicely to the gut in a preclinical model. And after a couple of hours, its effects dissipate,” Lee said.

The team is now testing the effect of short-and long-term use of LuCI in diabetic and obese rodent models. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

New Drug Offers Treatment For Diabetes-Related Blindness

The researchers now plan to conduct a full-scale clinical trial, Gamble said

0
new policy will see the launch of 12 programmes relevant to private schools across the emirate
New drug offers hope for diabetes-related blindness.

In a major breakthrough, Australian scientists have developed a new drug that offers treatment for people suffering from diabetic retinopathy — the main cause of blindness from diabetes.

The debilitating disease occurs when tiny blood vessels in the retina, responsible for detecting light, leak fluid or haemorrhage.

While treatment options include laser surgery or eye injections of anti-vascular endothelial growth factor (VEGF), they are not always effective or can result in side effects, highlighting the need for alternative therapeutic approaches.

The team from the Centenary Institute in Sydney developed a novel drug CD5-2, which in mouse models was found to mend the damaged blood retinal barrier and reduce vascular leakage.

“We believe CD5-2 could potentially be used as a stand-alone therapy to treat those patients who fail to respond to the anti-VEGF treatment. It may also work in conjunction with existing anti-VEGF treatments to extend the effectiveness of the treatment,” said lead author Ka Ka Ting from the Institute.

“With limited treatment options currently available, it is critical we develop alternative strategies for the treatment of this outcome of diabetes,” Ting added.

Diabetes
Representational image. Pixabay

The key process involved in diabetic retinopathy pathology is the breakdown of the blood-retinal barrier (BRB), which is normally impermeable. Its integrity relies on how well capillary endothelial cells are bound together by tight junctions. If the junctions are loose or damaged, the blood vessels can leak.

In the study, reported in the journal Diabetologia, CD5-2 was found to have therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction as well as inflammatory aspects in animal models of retinopathy.

Previous studies have shown that CD5-2 can have positive effects on the growth of blood vessels.

Also Read- Facebook Invests $1 mn To Boost Computer Science Education

“This drug has shown great promise for the treatment of several major health problems, in the eye and in the brain,” said Professor Jenny Gamble, head of Centenary’s Vascular Biology Programme.

The researchers now plan to conduct a full-scale clinical trial, Gamble said. (IANS)